ARCHIVES

Rituximab After CVP Improves Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 32 No. 3 | March 27, 2009

Download PDF Visit The Full Archive

Related Articles

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

FDA News< Regulations To Ease For Advertising Drugs On TV, Radio

September 12, 1997

CCIRC Fears Multimodality Studies Threatened By Cooperative Groups’ Misapplication Of Funds

January 14, 1977

DeVita Distressed Over “Misinformation” Circulation On Organ Systems Program

April 8, 1983

In Brief: Sandor Eckhardt Is New UICC President; New Delhi Is Site Of 1994 UICC Meeting

August 31, 1990

Proceedings Initiated Against Two Physicians At Dana-Farber

April 7, 1995